Jittery logo
> Financial Performance and Analysis

 What were Amgen's financial results for the previous fiscal year?

Amgen, a leading biotechnology company, reported its financial results for the previous fiscal year, which ended on December 31st. The company's performance during this period demonstrated its strong position in the industry and its ability to generate consistent revenue and profitability.

In terms of revenue, Amgen reported total product sales of $23.4 billion for the fiscal year. This represents a growth of 11% compared to the previous year. The increase in revenue was primarily driven by higher sales of key products, including Enbrel, Prolia, Xgeva, and Repatha. These products have continued to perform well in their respective therapeutic areas, contributing significantly to Amgen's top-line growth.

Amgen's operating income for the fiscal year was $8.2 billion, reflecting a margin of approximately 35%. This indicates the company's ability to effectively manage its costs and expenses while generating substantial profits. The operating income grew by 14% compared to the previous year, primarily due to higher revenue and improved operational efficiency.

Net income attributable to Amgen for the fiscal year was $7.5 billion, representing a growth of 8% compared to the previous year. This growth in net income can be attributed to the company's strong operating performance and effective tax management strategies. Amgen's earnings per share (EPS) for the fiscal year stood at $12.41, demonstrating a growth of 10% compared to the previous year.

Amgen also maintained a solid balance sheet during the fiscal year. The company reported cash, cash equivalents, and marketable securities of $9.8 billion, providing it with a strong financial position and flexibility for future investments and strategic initiatives. Additionally, Amgen generated $9.1 billion in operating cash flow, further highlighting its ability to generate substantial cash from its operations.

Overall, Amgen's financial results for the previous fiscal year reflect its strong market position, robust revenue growth, and effective cost management. The company's ability to consistently deliver solid financial performance underscores its commitment to innovation, research, and development in the biotechnology sector.

 How does Amgen's revenue compare to its competitors in the biotechnology industry?

 What factors contributed to Amgen's profitability in the last quarter?

 How has Amgen's stock performance been over the past five years?

 What is the trend in Amgen's operating expenses over the past decade?

 What is the breakdown of Amgen's revenue by geographic region?

 How does Amgen allocate its research and development budget?

 What are the key financial ratios used to evaluate Amgen's financial health?

 How does Amgen manage its working capital and cash flow?

 What is the impact of foreign currency exchange rates on Amgen's financial statements?

 What is Amgen's dividend policy and how has it evolved over time?

 How does Amgen manage its debt and leverage ratios?

 What are the main drivers of Amgen's revenue growth?

 How does Amgen's financial performance compare to industry benchmarks?

 What are the major risks and uncertainties that could impact Amgen's financial performance?

 How does Amgen's financial performance vary across its different product lines?

 What is the historical trend in Amgen's research and development expenses as a percentage of revenue?

 How does Amgen's financial performance differ between its domestic and international markets?

 What are the key factors influencing Amgen's gross margin and operating margin?

 How does Amgen manage its capital expenditures and long-term investments?

Next:  Amgen's Corporate Social Responsibility
Previous:  Amgen's Competitive Landscape

©2023 Jittery  ·  Sitemap